Agomelatine decreases cocaine-induced locomotor sensitisation and dopamine release in rats

References

• Barbosa-Méndez S, Matus-Ortega M, Flores-Zamora A, Jurado N, Salazar-Juárez A. 2017. Dose-and time-dependent effects of mirtazapine on the expression of cocaine-induced behavioral sensitization in rats. Psychiatry Res. 254:301–310.
   PubMed Web of Science ®Google Scholar
• Barbosa-Méndez S, Pérez-Sánchez G, Becerril-Villanueva E, Salazar-Juárez A. 2021. Melatonin decreases cocaine-induced locomotor sensitization and cocaine-conditioned place preference in rats. J Psychiatr Res. 132:97–110.
   PubMed Web of Science ®Google Scholar
• Barbosa-Méndez S, Salazar-Juárez A. 2020. Melatonin decreases cocaine-induced locomotor activity in pinealectomized rats. Braz J Psychiatry. 42(3):295–308.
   PubMedGoogle Scholar
• Becerril-Villanueva E, Ponce-Regalado MD, Pérez-Sánchez G, Salazar-Juárez A, Arreola R, Álvarez-Sánchez ME, Juárez-Ortega M, Falfán-Valencia R, Hernández-Pando R, Morales-Montor J, et al. 2018. Chronic infection with Mycobacterium lepraemurium induces alterations in the hippocampus associated with memory loss. Sci Rep. 8(1):9063.
   PubMedGoogle Scholar
• Benleulmi-Chaachoua A, Hegron A, Le Boulch M, Karamitri A, Wierzbicka M, Wong V, Stagljar I, Delagrange P, Ahmad R, Jockers R. 2018. Melatonin receptors limit dopamine reuptake by regulating dopamine transporter cell-surface exposure. Cell Mol Life Sci. 75(23):4357–4370.
   PubMed Web of Science ®Google Scholar
• Bertaina-Anglade V, Mocaër E, Drieu la Rochelle C. 2002. Antidepressant-like action of S 20098 (agomelatine) in the learned helplessness test. Int J Neuropsychopharmacol. 5(Suppl.1):S65.
   Google Scholar
• Bhutada P, Dixit P, Thakur K, Deshmukh P, Kaulaskar S. 2013. Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam. Kaohsiung J Med Sci. 29(7):362–367.
   PubMed Web of Science ®Google Scholar
• Bonnefond C, Martinet L, Lesieur D, Adam G, Guardiola-LemaÎtre B. 1993. Characterization of S 20098, a new melatonin analogue. In Touitou Y, Arendt J, Pevet P, editors. Melatonin and the pineal gland. New York: Elsevier; p. 123–126.
   Google Scholar
• Bourin M, Mocaër E, Porsolt R. 2004. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci. 29(2):126–133.
   PubMed Web of Science ®Google Scholar
• Buoli M, Grassi S, Serati M, Altamura AC. 2017. Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother. 18(13):1373–1379.
   PubMed Web of Science ®Google Scholar
• Buoli M, Mauri MC, Altamura AC. 2014. Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder. Expert Opin Drug Metab Toxicol. 10(6):885–892.
   PubMed Web of Science ®Google Scholar
• Carocci A, Catalano A, Sinicropi MS. 2014. Melatonergic drugs in development. Clin Pharmacol. 6:127–137.
   PubMedGoogle Scholar
• Clough SJ, Hutchinson AJ, Hudson RL, Dubocovich ML. 2014. Genetic deletion of the MT1 or MT2 melatonin receptors abrogates methamphetamine-induced reward in C3H/HeN mice. Physiol Behav. 132:79–86.
   PubMed Web of Science ®Google Scholar
• Di Chiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA. 85(14):5274–5278.
   PubMed Web of Science ®Google Scholar
• Dubocovich ML, Mogilnicka E, Areso PM. 1990. Antidepressant-like activity of the melatonin receptor antagonist, luzindole (N-0774), in the mouse behavior despair test. Eur J Pharmacol. 182(2):313–325.
   PubMed Web of Science ®Google Scholar
• Dubocovich ML. 1983. Melatonin is a potent modulator of dopamine release in the retina. Nature. 306(5945):782–784.
   PubMed Web of Science ®Google Scholar
• Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, Robbins TW. 2008. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci. 363(1507):3125–3135.
   PubMed Web of Science ®Google Scholar
• Fathi D, Abulsoud AI, Saad MA, Nassar NN, Maksimos MM, Rizk SM, Senousy MA. 2021. Agomelatine attenuates alcohol craving and withdrawal symptoms by modulating the Notch1 signaling pathway in rats. Life Sci. 284:119904.
   PubMed Web of Science ®Google Scholar
• Gahr M. 2014. Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks. Curr Neuropharmacol. 12(5):287–398.
   PubMed Web of Science ®Google Scholar
• Gorwood P, Benichou J, Moore N, Álvarez Martínez E, Mertens J, Aguglia E, Figueira ML, Falkai P, Olivier V, Wattez M, et al. 2021. The safety of agomelatine in standard medical practice in depressed patients: a 26-week international multicentre cohort study. Hum Psychopharmacol. 36(1):1–11.
   PubMed Web of Science ®Google Scholar
• Grosshans M, Mutschler J, Luderer M, Mann K, Kiefer F. 2014. Agomelatine is effective in reducing insomnia in abstinent alcohol-dependent patients. Clin Neuropharmacol. 37(1):6–8.
   PubMed Web of Science ®Google Scholar
• Han J, Xu Y, Yu CX, Shen J, Wei YM. 2008. Melatonin reverses the expression of morphine-induced conditioned place preference through its receptors within central nervous system in mice. Eur J Pharmacol. 594:125–131.
   PubMed Web of Science ®Google Scholar
• Harmer CJ, de Bodinat C, Dawson GR, Dourish CT, Waldenmaier L, Adams S, Cowen PJ, Goodwin GM. 2011. Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. J Psychopharmacol. 25(9):1159–1167.
   PubMed Web of Science ®Google Scholar
• Horton WJ, Gissel HJ, Saboy JE, Wright KP, Stitzel JA. 2015. Melatonin administration alters nicotine preference consumption via signaling through high-affinity melatonin receptors. Psychopharmacology. 232(14):2519–2530.
   PubMed Web of Science ®Google Scholar
• Hutchinson AJ, Hudson RL, Dubocovich ML. 2012. Genetic deletion of MT(1) and MT(2) melatonin receptors differentially abrogates the development and expression of methamphetamine-induced locomotor sensitization during the day and the night in C3H/HeN mice. J Pineal Res. 53(4):399–409.
   PubMed Web of Science ®Google Scholar
• Hutchinson AJ, Ma J, Liu J, Hudson RL, Dubocovich ML. 2014. Role of MT1 melatonin receptors in methamphetamine-induced locomotor sensitization in C57BL/6 mice. Psychopharmacology. 231(1):257–267.
   PubMed Web of Science ®Google Scholar
• Kalivas PW, Duffy P. 1993a. Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci. 13(1):266–275.
   PubMed Web of Science ®Google Scholar
• Kalivas PW, Duffy P. 1993b. Time course of extracellular dopamine and behavioral sensitization to cocaine. II. Dopamine perikarya. J Neurosci. 13(1):276–284.
   PubMed Web of Science ®Google Scholar
• Kasper S, Hamon M. 2009. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry. 10(2):117–126.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Avedisova A, Belaïdi C, Picarel-Blanchot F, de Bodinat C. 2016. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol. 26(2):378–389.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Eisfeld BS. 2007. Agomelatine and its therapeutic potential in the depressed patient. Neuropsychiatr Dis Treat. 3(4):423–428.
   PubMedGoogle Scholar
• Khaldy H, León J, Escames G, Bikjdaouene L, García JJ, Acuña-Castroviejo D. 2002. Circadian rhythms of dopamine and dihydroxyphenyl acetic acid in the mouse striatum: effects of pinealectomy and of melatonin treatment. Neuroendocrinology. 75(3):201–208.
   PubMed Web of Science ®Google Scholar
• Kleijn J, Folgering JH, van der Hart MC, Rollema H, Cremers TI, Westerink BH. 2011. Direct effect of nicotine on mesolimbic dopamine release in rat nucleus accumbens shell. Neurosci Lett. 493(1–2):55–58.
   PubMed Web of Science ®Google Scholar
• Lin SH, Huang YN, Kao JH, Tien LT, Tsai RY, Wong CS. 2016. Melatonin reverses morphine tolerance by inhibiting microglia activation and HSP27 expression. Life Sci. 152:38–43.
   PubMed Web of Science ®Google Scholar
• Lôo H, Hale A, D'haenen H. 2002. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 17(5):239–247.
   PubMed Web of Science ®Google Scholar
• Manikandan S. 2010. Agomelatine: a novel melatonergic antidepressant. J Pharmacol Pharmacother. 1(2):122–123.
   PubMedGoogle Scholar
• Millan MJ, Brocco M, Gobert A, Dekeyne A. 2005. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology. 177(4):448–458.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D. 2003. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 306(3):954–964.
   PubMed Web of Science ®Google Scholar
• Norman TR, Cranston I, Irons JA, Gabriel C, Dekeyne A, Millan MJ, Mocaër E. 2012. Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and the 5-HT(2c) antagonist, S32006. Eur J Pharmacol. 674(1):27–32.
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, Cardinali DP. 2008. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 85(3):335–353.
   PubMed Web of Science ®Google Scholar
• Papp M, Gruca P, Boyer PA, Mocaër E. 2003. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology. 28(4):694–703.
   PubMed Web of Science ®Google Scholar
• Papp M, Litwa E, Gruca P, Mocaër E. 2006. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol. 17(1):9–18.
   PubMed Web of Science ®Google Scholar
• Raghavendra V, Kulkarni SK. 2000. Possible mechanisms of action in melatonin reversal of morphine tolerance and dependence in mice. Eur J Pharmacol. 409:279–289.
   PubMed Web of Science ®Google Scholar
• Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, Armstrong SM. 1995. Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology. 118(4):385–390.
   PubMed Web of Science ®Google Scholar
• Rouillon F. 2006. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol. 21(Supplement 1):S31–S35.
   PubMedGoogle Scholar
• Salazar-Juárez A, Barbosa-Méndez S, Jurado N, Hernández-Miramontes R, Leff P, Antón B. 2016. Mirtazapine prevents induction and expression of cocaine-induced behavioral sensitization in rats. Prog Neuropsychopharmacol Biol Psychiatry. 68:15–24.
   PubMed Web of Science ®Google Scholar
• San L, Arranz B. 2008. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry. 23(6):396–402.
   PubMed Web of Science ®Google Scholar
• Schiller ED, Champney TH, Reiter CK, Dohrman DP. 2003. Melatonin inhibition of nicotine-stimulated dopamine release in PC12 cells. Brain Res. 966(1):95–102.
   PubMed Web of Science ®Google Scholar
• Sircar R. 2000. Effect of melatonin on cocaine-induced behavioral sensitization. Brain Res. 857(1–2):295–299.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Khoo JP, Picarel-Blanchot F, Olivier V, Van Ameringen M. 2021. Efficacy of Agomelatine 25–50 mg for the treatment of anxious symptoms and functional impairment in generalized anxiety disorder: a meta-analysis of three placebo-controlled studies. Adv Ther. 38(3):1567–1583.
   PubMed Web of Science ®Google Scholar
• Takahashi TT, Vengeliene V, Spanagel R. 2017. Melatonin reduces motivation for cocaine self-administration and prevents relapse-like behavior in rats. Psychopharmacology. 234(11):1741–1748.
   PubMed Web of Science ®Google Scholar
• Tchekalarova J, Atanasova D, Kortenska L, Atanasova M, Lazarov N. 2018. Chronic agomelatine treatment prevents comorbid depression in the post-status epilepticus model of acquired epilepsy through suppression of inflammatory signaling. Neurobiol Dis. 115:127–144.
   PubMed Web of Science ®Google Scholar
• Tchekalarova J, Nenchovska Z, Atanasova D, Atanasova M, Kortenska L, Stefanova M, Alova L, Lazarov N. 2016. Consequences of long-term treatment with agomelatine on depressive-like behavior and neurobiological abnormalities in pinealectomized rats. Behav Brain Res. 302:11–28.
   PubMed Web of Science ®Google Scholar
• Tchekalarova J, Stoynova T, Ilieva K, Mitreva R, Atanasova M. 2018. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light. Pharmacol Biochem Behav. 171:1–9.
   PubMed Web of Science ®Google Scholar
• Todtenkopf MS, Mihalakopoulos A, Stella JR. 2002. Withdrawal duration differentially affects c-fos expression in the medial prefrontal cortex and discrete subregions of the nucleus accumbens in cocaine-sensitized rats. Neuroscience. 114(4):1061–1069.
   PubMed Web of Science ®Google Scholar
• Uz T, Arslan AD, Kurtuncu M, Imbesi M, Akhisaroglu M, Dwivedi Y, Pandey GN, Manev H. 2005. The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. Brain Res Mol Brain Res. 136(1–2):45–53.
   PubMedGoogle Scholar
• Vanderschuren LJ, Pierce RC. 2010. Sensitization processes in drug addiction. Curr Top Behav Neurosci. 3:179–195.
   PubMedGoogle Scholar
• Vanderschuren LJ, Kalivas PW. 2000. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology. 151(2–3):99–120.
   PubMed Web of Science ®Google Scholar
• Vengeliene V, Noori HR, Spanagel R. 2015. Activation of melatonin receptors reduces relapse-like alcohol consumption. Neuropsychopharmacology. 40(13):2897–2906.
   PubMed Web of Science ®Google Scholar
• Wang SM, Woo YS, Kim NY, Na HR, Lim HK, Bahk WM. 2020. Agomelatine for the treatment of generalized anxiety disorder: a meta-analysis. Clin Psychopharmacol Neurosci. 18(3):423–433.
   PubMed Web of Science ®Google Scholar
• Wang SY, Shi XC, Laborda P. 2020. Indole-based melatonin analogues: synthetic approaches and biological activity. Eur J Med Chem. 185:111847.
   PubMed Web of Science ®Google Scholar
• Wiley JL, Dance ME, Balster RL. 1998. Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S-20098), a melatonin agonist. Psychopharmacology. 140(4):503–509.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhu D, Zhang J, Li G, Liu Z, Sun J. 2016. Melatonin treatment during the incubation of sensitization attenuates methamphetamine-induced locomotor sensitization and MeCP2 expression. Prog Neuropsychopharmacol Biol Psychiatry. 65:145–152.
   PubMed Web of Science ®Google Scholar
• Ying SW, Rusak B, Delagrange P, Mocaër E, Renard P, Guardiola-LemaÎtre B. 1996. Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. Eur J Pharmacol. 296(1):33–42.
   PubMed Web of Science ®Google Scholar
• Yous S, Andrieux J, Howell HE, Morgan PJ, Renard P, Pfeiffer B, Lesieur D, Guardiola-Lemaitre B. 1992. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem. 35(8):1484–61486.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Silveyra E, Jin N, Ribelayga CP. 2018. A congenic line of the C57BL/6J mouse strain that is proficient in melatonin synthesis. J Pineal Res. 65(3):e12509.
   PubMed Web of Science ®Google Scholar
• Zlotos DP. 2012. Recent progress in the development of agonists and antagonists for melatonin receptors. Curr Med Chem. 19:3532–3549.
   PubMed Web of Science ®Google Scholar